NasdaqGM:IOVABiotechs
Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation
Iovance Biotherapeutics (IOVA) drew fresh attention after reporting its fourth quarter and full year 2025 results, with revenue of US$86.77 million for the quarter and US$263.5 million for the year.
See our latest analysis for Iovance Biotherapeutics.
The recent earnings release and news flow have gone hand in hand with a sharp shift in sentiment. The 30 day share price return of 51.37% and 90 day share price return of 80.80% contrast with a 1 year total shareholder return decline of 4.46% as...